T 0814/22 (Everolimus and aromatase inhibitors/NOVARTIS) of 28.07.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T081422.20230728
- Date of decision
- 28 July 2023
- Case number
- T 0814/22
- Petition for review of
- -
- Application number
- 18155644.0
- IPC class
- A61P 35/04A61P 35/00A61K 31/436
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- RAPAMYCIN DERIVATIVE FOR THE TREATMENT OF A SOLID TUMOR ASSOCIATED WITH DEREGULATED ANGIOGENESIS
- Applicant name
- Novartis Pharma AG
- Opponent name
- STADA Arzneimittel AG
BIOGARAN
Ethypharm
Accord Healthcare Ltd
Zentiva Pharma GmbH
Dr. Reddy's Laboratories Ltd./ Betapharm
Arzneimittel GmbH
Generics [UK] Limited
Teva Pharmaceutical Industries Ltd.
ARROW GENERIQUES - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56
- Keywords
- Inventive step - obvious modification
- Catchword
- -
- Cited cases
- -
- Citing cases
- T 1796/22
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.